allowing us to progress re-dosable gene therapies with drug titration capabilities and engineered tropism to reach the targeted cells whatever the size of the gene involved.
Non-viral
DNA-based
medicine
Tyris Pipeline
Research
Proof-to-principle
In vitro In vivo
Pre-clinical Development
Systemic Delivery
Hemophilia A/
Factor VIII
Local Delivery
Epidermolysis Bullosa/
Collagen VII
Tyris Pipeline
Proprietary oDNA™
Tyris proprietary oDNA™ is an unprecedented synthetic linear closed DNA format.
01
what is it?
Our oDNA™ are only made of the transgene (e.g. gene of interest, promoter, enhancer) and other key sequences if required (e.g. ITRs), along with our proprietary adaptors.
02
What does it do?
Provides a unique differentiation over plasmid and other DNA formats, since it can be uniquely optimized on a project basis for achieving an unprecedented modulation and enhancement of desired transgene properties.
Non-Viral delivery technology
Provides versatile nanosized 3D architecture and broad functionality possibilities.
01
Does not trigger immune response
02
Unlimited cargo loading capacity
03
Engineered and functionalized to targeted biodistribution and cell delivery
Next generation gene therapy
Our unique technology platform enables us to progress ground-breaking gene therapies with life-changing benefits not only for patients suffering from diseases already addressed by existing gene therapies, but also for those left with no treatment because of current platforms limitations.
01.
Redosing ability to provide lifelong control of the disease
02.
Drug titration to deliver personalized treatment response
03.
Targeted biodistribution to organs and specific cell types
04.
No transgene size limitation to tackle a wide range of diseases
05.
oDNA™ versatile modulation of transgene properties
06.
oDNA™ free of antibiotic resistance and any bacterial sequences
